Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07339059 · ClinicalTrials.gov registry record · Phase 2
SG and Immunotherapy as Maintenance Therapy for Extensive-stage Small-cell Lung Cancer
A Phase 2 study of Extensive Stage Small Cell Lung Cancer (ES-SCLC) and Small Cell Lung Cancer (SCLC ), sponsored by Bindu R Potugari.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
- 1
- Study location
NCT07339059 is a Phase 2 study of Extensive Stage Small Cell Lung Cancer (ES-SCLC) and Small Cell Lung Cancer (SCLC ) that is actively recruiting participants, run by Bindu R Potugari. The registered enrollment target is 35 participants, below the 309-participant average among 3 other Extensive Stage Small Cell Lung Cancer (ES-SCLC) trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07339059, a Phase 2 study of Extensive Stage Small Cell Lung Cancer (ES-SCLC) and Small Cell Lung Cancer (SCLC ), is actively recruiting participants, sponsored by Bindu R Potugari.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to learn if the combination of sacituzumab govetican (SG) and atezolizumab/durvalumab is effective in controlling cancer tumor growth in adults with extensive stage small cell lung cancer. These drugs are FDA approved individually in different cancers. This combination is evaluated in breast cancer and showed promising combination. The effectiveness of this treatment combination will be measured by changes in tumor size and appearance of new tumors. Participants in the trial will: * receive treatment SG and immunotherapy every 21 days for up to 2 years or until it is no longer works for the patient. * CT scans at 6weeks for first 6 cycles and then every 9-12 weeks and MRI brain every 12 weeks. * provide tissue (optional) and blood for additional testing (learn about the cancer).
Conditions Studied
Interventions
- DRUG Sacituzumab govitecan
- DRUG Atezolizumab
- DRUG Durvalumab
Study Locations (1)
Michigan
- Henry Ford Cancer- Detroit - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2026-02-01 |
| Est. Completion | 2029-12-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07339059
The ClinicalTrials.gov registry entry for NCT07339059 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 309-participant average among 3 other Extensive Stage Small Cell Lung Cancer (ES-SCLC) trials with a reported enrollment target (89% lower). The listed sponsor is Bindu R Potugari, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Extensive Stage Small Cell Lung Cancer (ES-SCLC) appearing as the primary indexed condition, and to 3 interventions - of which Sacituzumab govitecan is the first listed.
NCT07339059 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT07339059 about?
NCT07339059 is a clinical study titled "SG and Immunotherapy as Maintenance Therapy for Extensive-stage Small-cell Lung Cancer". The goal of this clinical trial is to learn if the combination of sacituzumab govetican (SG) and atezolizumab/durvalumab is effective in controlling cancer tumor growth in adults with extensive stage small cell lung cancer. These drugs are FDA approved individually in different cancers. This combina...
What is the current status of trial NCT07339059?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2026-02-01. Estimated completion is 2029-12-01.
What conditions does trial NCT07339059 study?
This clinical trial studies the following conditions: Extensive Stage Small Cell Lung Cancer (ES-SCLC), Small Cell Lung Cancer (SCLC ).
What interventions are being tested in trial NCT07339059?
The interventions under investigation include: Sacituzumab govitecan (DRUG), Atezolizumab (DRUG), Durvalumab (DRUG).
Who is sponsoring clinical trial NCT07339059?
This trial is sponsored by Bindu R Potugari, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07339059 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Iadademstat + SBRT With Atezo in ES-SCLC
RECRUITING · Phase 1
-
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
RECRUITING · Phase 3
Explore more on PlainTrial
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
All registered trials for this condition
Small Cell Lung Cancer (SCLC )
All registered trials for this condition
Michigan
All trials with a study site in Michigan
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.